Skip to main content
Equibles
VREOF logo

VREOF · Vireo Growth Inc.

Track VREOF — free

Use VREOF with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about VREOF

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$10.96 +0.16 (+1.48%) At close · Aug 17
Market Cap
$527.67M
Shares
48.06M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.96 Open$10.84 Day$10.83–11.05 Since split$9.37–13.55 Avg vol 30d23K Short int3K · 0.0% float · 1.0d Short vol20% Last earningsAug 11, 2026 DataJun 2026–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Jun 5, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Jun 5, 2026.

Up next

Next earnings call
Nov 10, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Limited Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 15.2 · calm Equity put/call 0.65
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 50-day avg +5%
above
RSI (14) 63
neutral
MACD trend Positive
52-week position 38%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.01% of float · ▲ +190.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Squeeze score 42
elevated · 0–100
Fundamentals
Strong
Revenue growth +170%
Y/Y
Gross margin 47%
contracting
EPS growth +44%
Y/Y
Free cash flow $-24.6M
Balance sheet $58.0M
net debt
Quant / Vol
risk profile
Moderate
Volatility 40%
annualized · 1-yr
Max drawdown −31%
past year
ATR 3.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+5% Bullish
RSI (14)
63 Neutral
MACD trend
Positive Bullish
52-week position
38% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.01% of float · ▲ +190.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1 holders — 13F breadth
Price context
position in its range since split · 2026-06-05
Range low $9 Now $11 · 38% Range high $14
vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Cannabis EBITDA (non-GAAP) non-GAAP $39.4M Three Months Ended June 30, 2026 —
Adjusted Cannabis EBITDA Margin non-GAAP 22.4% Three Months Ended June 30, 2026 —
Adjusted Cannabis Gross Profit non-GAAP $92.4M Three Months Ended June 30, 2026 —
Adjusted Cannabis Gross Profit Margin non-GAAP 52.6% Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP EBITDA (non-GAAP) $33.1M
+$1.9M Non-cash inventory adjustments
+$0M Grown Rogue termination fee included in cost of goods sold
-$2.9M Change in the fair value of contingent consideration
+$7.5M Stock-based compensation
+$19.7M Transaction related expenses
+$2.4M One time legal costs
-$1.2M Other (income) expense
-$21.7M Bargain purchase gain
+$0M Severance expense
+$0.6M Loss on disposal of assets
= Adjusted EBITDA (non-GAAP) $39.4M
Adjusted EBITDA Margin non-GAAP 19.8% Three Months Ended June 30, 2026 —
Adjusted Gross Profit Margin non-GAAP 47% Three Months Ended June 30, 2026 —
Adjusted Non-Cannabis EBITDA (non-GAAP) non-GAAP $2.1M Three Months Ended June 30, 2026 —
Adjusted Non-Cannabis EBITDA Margin non-GAAP 6.3% Three Months Ended June 30, 2026 —
Adjusted Non-Cannabis Gross Profit non-GAAP $6M Three Months Ended June 30, 2026 —
Adjusted Non-Cannabis Gross Profit Margin non-GAAP 17.9% Three Months Ended June 30, 2026 —
EBITDA (non-GAAP) non-GAAP $34M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income (loss) $0.2M
+$9.2M Interest expense, net
+$14.3M Income taxes
+$5.8M Depreciation & Amortization
+$3.6M Depreciation and amortization included in cost of sales
= EBITDA (non-GAAP) $33.1M
Subordinate voting shares outstanding 54.4M As of June 30, 2026 —
Pro Forma Cannabis Adjusted EBITDA non-GAAP $40.1M Three Months Ended March 31, 2026 —
Pro Forma Cannabis Revenue non-GAAP $183.7M Three Months Ended March 31, 2026 —
Pro Forma Non-Cannabis Adjusted EBITDA non-GAAP $2.1M Three Months Ended March 31, 2026 —
Pro Forma Non-Cannabis Revenue non-GAAP $26.5M Three Months Ended March 31, 2026 —
Pro Forma Revenue non-GAAP $210.2M Three Months Ended March 31, 2026 —
Pro Forma same store sales growth non-GAAP 22% Q4 2025 —
Pro Forma same store sales growth excluding Minnesota non-GAAP 11.3% Q4 2025 —
Pro Forma wholesale revenue growth non-GAAP 55% Q4 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VREOF
Vireo Growth Inc.
this stock
$527.67M — +170.4% — 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $64.91B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $57.75B +11.5% — — 0.1%
GALDY
Galderma Group AG/ADR
 $48.51B +0.5% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $42.63B +16.8% +4.3% 60.0 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1
% held
0.0%
Net QoQ
+333 sh
Top holder
RESOURCES MANAGEMENT CORP…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
2.7K
Days to cover
1.0d
Change
+1.8K sh
View
Short Volume
Short vol %
20%
As of
Aug 18, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$10.9K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$268.8M
Net income (FY)
$-68.1M
EPS diluted
$-2.70
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 18, 2026
This year
26
View
Exempt Offerings
Offering
$1.1M
Filed
Jun 29, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 11, 2026
View
Investor Relations
Latest news
Vireo Growth Inc. to Acquire Plan…
Published
Jul 27, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 5, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
VREOF +3.0% +11.8% — +16.1% —
SPY -0.1% +4.1% +12.4% +3.4% +13.3%
vs SPY +3.1% +7.7% — +12.7% —
Key facts CIK 1771706 CUSIP 92767B204 Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)